Parecoxib is used in clinical settings for the management of pain, including postoperative pain where appropriate. The approval supports Invengene’s objective of expanding access to essential, high-quality injectable medicines through strong development fundamentals and reliable regulatory execution.

Saudi Arabia represents a strategic market for Invengene’s international expansion plans. The approval reflects the company’s ability to meet market-specific expectations and documentation requirements, supported by cross-functional coordination across R&D, quality, regulatory, and partner teams.

This milestone also reinforces Invengene’s approach to growth: identify meaningful products, build them to global standards, and work with trusted partners to deliver reliably.

“Saudi Arabia is an important market as we deepen our presence across the Middle East,” said Dr. Ankur Shah, Chairman & Managing Director, Invengene Private Limited. “We will continue to expand our portfolio and partnerships in the region with the same emphasis on quality and consistency.”

Invengene will continue working with its regional partners to support launch readiness and ensure timely availability, in line with local requirements and supply planning.